Medical Article

In addition to pricing the biggest biotech IPO of the week, Braveheart Bio’s underwriters exercised their option to purchase more shares, boosting the clinical-stage company’s total haul to nearly $440 million. Braveheart’s lead drug could be competitive with a blockbuster Bristol Myers Squibb medicine for a type of cardiomyopathy. The post Braveheart Bio’s $382M IPO…

In this episode, we’re joined by Cheryl Larson, president and CEO of the Midwest Business Group on Health, for our first in-person recording at MedCity News’ recent Bullseye event. The post MedCity FemFwd: Employer Strategies for Women’s Health appeared first on MedCity News.

Hinge Health’s acquisition of Cylinder expands it into GI care, but experts differ on whether employers will favor convenience or specialized solutions. The post Two Differing POVs Emerge About the Hinge-Cylinder Deal appeared first on MedCity News.

Latigo Biotherapeutics will apply the IPO proceeds toward a pipeline that includes a next-generation non-opioid pain drug ready for pivotal testing. BlossomHill Therapeutics also debuted on the Nasdaq, raising cash for cancer drugs designed to address mutations not covered by currently available therapies. The post Latigo Bio’s IPO Lands $346M for Pipeline of Non-Opioid Pain…

The problem may not be the investment. It may be the target of the intervention. The post Why Kidney Care’s Biggest Investment Wave Hasn’t Moved Hospital Costs appeared first on MedCity News.

A letter to Medicaid Directors, State Leaders, and other invested collaborators who were awarded Rural Health Transformation (RHT) Grant funding. The post My Wish For Better Care For Americans Living in Rural Areas appeared first on MedCity News.

A bipartisan group of six senators introduced a bill to reform the 340B drug program, locking in hospitals’ use of contract pharmacies and adding new transparency and compliance rules. The legislation would also kill HHS’ contested rebate pilot within a year and replace it with a national data clearinghouse to catch duplicate discounts. The post…

Replimune went from an FDA rejection to a resubmission, a positive advisory committee vote, and finally an accelerated regulatory approval for advanced melanoma — all in less than four months. The FDA nod for Replimune’s oncolytic viral therapy, Tudriqev, positions it as a more convenient alternative to an Iovance Biotherapeutics cell therapy that had been…

Democratic senators are urging CMS to withdraw its Medicaid work requirements rule, arguing it will create administrative burdens and cause eligible beneficiaries to lose coverage. The post Democratic Senators Urge Withdrawal of Interim Final Rule on Medicaid Work Requirements appeared first on MedCity News.